Cardiol Therapeutics Inc. (CRDL)
USD 1.14
(1.79%)
USD 1.14
(1.79%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 29.78 Million CAD | -27.94% |
| 2022 | 41.33 Million CAD | 6.69% |
| 2021 | 38.74 Million CAD | 87.25% |
| 2020 | 20.69 Million CAD | 46.45% |
| 2019 | 14.12 Million CAD | 88.53% |
| 2018 | 7.49 Million CAD | 369.7% |
| 2017 | 1.59 Million CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 8.34 Million CAD | 4.8% |
| 2024 Q2 | 7.67 Million CAD | -7.22% |
| 2023 Q3 | 7.65 Million CAD | 21.24% |
| 2023 FY | 29.53 Million CAD | -28.54% |
| 2023 Q1 | 7.78 Million CAD | -14.39% |
| 2023 Q2 | 6.31 Million CAD | -18.9% |
| 2023 Q4 | 7.96 Million CAD | 4.0% |
| 2022 FY | 41.33 Million CAD | 6.69% |
| 2022 Q1 | 9.78 Million CAD | -25.27% |
| 2022 Q4 | 9.09 Million CAD | -31.2% |
| 2022 Q3 | 13.22 Million CAD | 43.2% |
| 2022 Q2 | 9.23 Million CAD | -5.68% |
| 2021 Q3 | 10.16 Million CAD | 56.31% |
| 2021 Q4 | 13.09 Million CAD | 28.87% |
| 2021 Q2 | 6.5 Million CAD | -27.6% |
| 2021 FY | 38.74 Million CAD | 87.25% |
| 2021 Q1 | 8.98 Million CAD | -6.64% |
| 2020 FY | 20.69 Million CAD | 46.45% |
| 2020 Q3 | 4.41 Million CAD | 23.07% |
| 2020 Q2 | 3.58 Million CAD | 16.48% |
| 2020 Q1 | 3.07 Million CAD | -6.51% |
| 2020 Q4 | 9.61 Million CAD | 118.07% |
| 2019 Q3 | 3.58 Million CAD | -4.52% |
| 2019 FY | 14.12 Million CAD | 88.53% |
| 2019 Q4 | 3.29 Million CAD | -8.17% |
| 2019 Q1 | 3.49 Million CAD | 6.88% |
| 2019 Q2 | 3.75 Million CAD | 7.28% |
| 2018 Q1 | 534.73 Thousand CAD | -6.39% |
| 2018 Q3 | 2.43 Million CAD | 94.92% |
| 2018 Q4 | 3.27 Million CAD | 34.4% |
| 2018 FY | 7.49 Million CAD | 369.7% |
| 2018 Q2 | 1.24 Million CAD | 133.69% |
| 2017 Q2 | 430.05 Thousand CAD | 0.0% |
| 2017 FY | 1.59 Million CAD | 0.0% |
| 2017 Q4 | 571.22 Thousand CAD | 12.59% |
| 2017 Q3 | 507.37 Thousand CAD | 17.98% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | 271.89 Million USD | 89.045% |
| Theratechnologies Inc. | 72.75 Million USD | 59.061% |
| Safety Shot Inc | 12.1 Million USD | -145.964% |
| Cosmos Health Inc. | 26.18 Million USD | -13.769% |
| Cronos Group Inc. | 96.7 Million USD | 69.201% |
| Ironwood Pharmaceuticals, Inc. | 232.12 Million USD | 87.168% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | 23.925% |
| Organogenesis Holdings Inc. | 314.13 Million USD | 90.518% |
| Universe Pharmaceuticals INC | 13.84 Million USD | -115.184% |
| ProPhase Labs, Inc. | 37.85 Million USD | 21.311% |
| Sonoma Pharmaceuticals, Inc. | 9.44 Million USD | -215.324% |
| Dynavax Technologies Corporation | 219.14 Million USD | 86.408% |
| Radius Health, Inc. | 265.92 Million USD | 88.799% |
| China SXT Pharmaceuticals, Inc. | 3.06 Million USD | -870.469% |
| Alvotech | 285.43 Million USD | 89.565% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -126.946% |
| Alpha Teknova, Inc. | 45.85 Million USD | 35.05% |
| Intra-Cellular Therapies, Inc. | 590 Million USD | 94.952% |
| SCYNEXIS, Inc. | 51.84 Million USD | 42.552% |
| Harrow Health, Inc. | 89.97 Million USD | 66.895% |
| Biofrontera Inc. | 39.95 Million USD | 25.46% |
| DURECT Corporation | 43.71 Million USD | 31.864% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 94.37% |
| ANI Pharmaceuticals, Inc. | 195.98 Million USD | 84.802% |
| OptiNose, Inc. | 85.1 Million USD | 65.0% |
| RedHill Biopharma Ltd. | -9.56 Million USD | 411.531% |
| Aquestive Therapeutics, Inc. | 44.85 Million USD | 33.595% |
| Cumberland Pharmaceuticals Inc. | 43.04 Million USD | 30.797% |
| SIGA Technologies, Inc. | 22.04 Million USD | -35.124% |
| Lifecore Biomedical, Inc. | 49.03 Million USD | 39.26% |
| Shineco, Inc. | 17.94 Million USD | -65.954% |
| Phibro Animal Health Corporation | 260.29 Million USD | 88.557% |
| Procaps Group S.A. | 187.24 Million USD | 84.093% |
| TherapeuticsMD, Inc. | 9.82 Million USD | -203.16% |
| Regencell Bioscience Holdings Limited | 3.99 Million USD | -646.291% |
| Viatris Inc. | 5.96 Billion USD | 99.501% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -126.946% |
| Rockwell Medical, Inc. | 15.37 Million USD | -93.739% |
| Incannex Healthcare Limited | 30.05 Million USD | 0.89% |
| Aytu BioPharma, Inc. | 59.84 Million USD | 50.225% |
| Tilray Brands, Inc. | 251.35 Million USD | 88.15% |
| Collegium Pharmaceutical, Inc. | 159.2 Million USD | 81.291% |
| PetIQ, Inc. | 192.72 Million USD | 84.545% |
| Silver Spike Investment Corp. | 762.49 Thousand USD | -3806.337% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 98.134% |
| Journey Medical Corporation | 54.59 Million USD | 45.442% |
| Alimera Sciences, Inc. | 62.64 Million USD | 52.45% |
| Petros Pharmaceuticals, Inc. | 17.8 Million USD | -67.254% |
| Assertio Holdings, Inc. | 368.58 Million USD | 91.919% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.88 Million USD | -406.077% |
| Embecta Corp. | 528.4 Million USD | 94.363% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -41.552% |
| Procaps Group, S.A. | 199.47 Million USD | 85.068% |
| PainReform Ltd. | 9.58 Million USD | -210.784% |
| Avadel Pharmaceuticals plc | 164.96 Million USD | 81.944% |
| Hempacco Co., Inc. | 7.59 Million USD | -292.098% |
| Talphera, Inc. | 11.99 Million USD | -148.337% |
| Pacira BioSciences, Inc. | 326.37 Million USD | 90.874% |
| Alvotech | 285.43 Million USD | 89.565% |
| Lantheus Holdings, Inc. | 344.9 Million USD | 91.364% |
| Kamada Ltd. | 45.42 Million USD | 34.431% |
| Indivior PLC | 911 Million USD | 96.73% |
| Currenc Group, Inc. | 24 Million USD | -24.095% |
| Evoke Pharma, Inc. | 12.4 Million USD | -140.019% |
| Flora Growth Corp. | 10.57 Million USD | -181.553% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -41.552% |
| Evolus, Inc. | 189.75 Million USD | 84.304% |
| HUTCHMED (China) Limited | 436.23 Million USD | 93.172% |
| Amphastar Pharmaceuticals, Inc. | 154.13 Million USD | 80.676% |
| Akanda Corp. | 3.48 Million USD | -755.043% |